No material news briefings were available in the provided context for Gilead Sciences Inc. (GILD) as of early August 2026. The present report is therefore constructed from verified financial filings, insider transaction records, and macroeconomic data cited within [Brief - 2026-08-05].
For the trailing twelve months ending 2026-06-30, Gilead Sciences recorded revenue of approximately $30.46 billion, representing year-over-year growth of 10.18%. Gross margin stood at 64.95%, while operating margin was -8.20% and net margin was -10.64%, producing a net loss of approximately $3.24 billion for the period. The company carried $3.18 billion in cash against total debt of $28.66 billion. Earnings per share declined sharply on a year-over-year basis, down 641.67%, rendering the price-to-earnings ratio not applicable. Market capitalisation was recorded at approximately $168.6 billion [SEC 10-Q - GILD - 2026-06-30].
Insider activity over the past 30 days comprised seven transactions with a net selling direction, aggregating a net disposal value of approximately $2.73 million [SEC Form 4 - GILD - 2026-08]. No 13F institutional holding changes were available in the provided context for this reporting period.
The prevailing macroeconomic backdrop features a 10-year US Treasury yield of 4.70% and a 2-year yield of 4.22%, producing a normal yield curve spread of 48 basis points [FRED DGS10; FRED DGS2]. This interest rate environment is relevant context for a company carrying $28.66 billion in total debt, as refinancing costs and debt servicing obligations are influenced by prevailing benchmark rates.
This report was triggered by a new SEC filing submitted in connection with Gilead Sciences' most recently completed fiscal quarter ending 2026-06-30, prompting a review of updated financial disclosures and associated insider transaction data.